概要：少数几个研究分析了慢性HCV治疗患者中HCV标记物的演化。我们评估了血清和肝脏HCV-RNA的有或无，核心抗原（HCV-cAg）和特异性抗体的缺失（抗-HCV），在长期持续性应答（SR）。共176位患者（其中132SR和44位无应答）纳入研究。血清和肝脏HCV-RNA的测定采用商品化的PCR试剂盒进行检测，HCV-eAg采用ELISA法，特异性抗-HCV抗体采用商品化的线性免疫印迹技术（LIA）检测。在持续应答的132位患者中有3人（4.2%）血清HCV-eAg阳性。4为SR（3.6%）和44位NR（100%）者肝组织中HCV-RNA阳性。两位患者HCV-eAg阳性。这与HCV-eAg和HCV-RNA的血清学水平具有很好的相关性（r=0.847，P<0.001）。在45位患者采用LIA法检测到特异性抗体（抗-HCV）。对持续随访大于5年SR患者与随访时间少于5年的SR和NR患者相比发现一些SR患者的E2和NS4片段的复活的几率降低（P值分别<0.01和0.005）。在慢性丙型肝炎治疗的患者中血清HCV-cAg和HCV-RNA水平之间具有很好的相关性（P<0.001）。少数SR（3.6%）肝脏具有HCV-RNA，和血清HCV-cAg阳性（1.8%）。在SR超过5年的随访期间，一个很明显趋势既是对血清中抗-HCV的E2和NS4片段的清除。

J Viral Hepat. 2006 Jan;13(1):28-33.

Long-term evolution of serum and liver viral markers in patients treated for chronic hepatitis C and sustained response.

Moreno M, Perez-Alvarez R, Rodrigo L, Perez-Lopez R, Suarez-Leiva P.

Gastroenterology, Hospital Central de Asturias, Oviedo, Spain.

Few studies have analysed the evolution of HCV markers in chronic hepatitis C (CHC)-treated patients. We have evaluated the presence or absence of serum and liver HCV-RNA, the core antigen (HCV-cAg) and the loss of specific antibodies (anti-HCV), in long-term sustained responders (SR). One hundred and seventy-six patients (132 SR and 44 nonresponders (NR) were included in the study. HCV-RNA was determined in serum and liver by a commercial PCR-kit. HCV-Ag was determined by ELISA and specific antibodies against HCV by means of a commercial line immunoblot assay (LIA) technique. Serum HCVcAg was found positive in three (4.2%) SR and in one (4%) NR (NS). Four SR (3.6%) and 44 NR (100%) were also HCV-RNA (+) in liver tissue. Two patients were HCV-cAg (+). A good correlation was found between the serum levels of HCV-cAg and HCV-RNA (r = 0.847, P < 0.001). Specific antibodies (anti-HCV) were determined by LIA in 45 patients. A decrease was found in the number of patients who presented reactivity to bands E2 and NS4 when we compared SR with a follow-up of more than 5 years with NR and SR with a follow-up <5 years (P < 0.01 and 0.005). A good correlation was found between the HCV-cAg and HCV-RNA serum levels in CHC-treated patients (P < 0.001). Few SR (3.6%) had HCV-RNA in the liver, and HCV-cAg (1.8%) in serum. In SR with more than 5 years of follow-up a clear tendency exists in the trend to clarify the bands E2 and NS4 of anti-HCV in serum.